Skip to main content
Actinium Pharmaceuticals, Inc. logo

Actinium Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ATNM ISIN · US00507W2061 LEI · 549300LCY1NZSXCQDT45 US Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2012-12-17 M&A Activity
Country US United States of America
Listing US ATNM

About Actinium Pharmaceuticals, Inc.

https://www.actiniumpharma.com/

Actinium Pharmaceuticals, Inc. is a clinical-stage company focused on developing targeted radiotherapies for patients with cancers lacking effective treatment options. The company's platform utilizes potent radioisotopes, such as the alpha-emitter Actinium-225, conjugated to monoclonal antibodies to precisely deliver radiation to cancer cells. Its clinical pipeline addresses hematologic malignancies and solid tumors. Key programs include Iomab-B, a targeted conditioning agent for bone marrow transplant in patients with relapsed or refractory Acute Myeloid Leukemia (AML), and Actimab-A, a CD33-targeting therapy for AML. The company is also advancing ATNM-400, a novel non-PSMA therapeutic for prostate cancer, and developing its proprietary Actinium-225 manufacturing technology and infrastructure.

Recent filings

Filing Released Lang Actions
FORM 8-K CURRENT REPORT
M&A Activity Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated August 30, 2012. It announces a letter of intent and a proposed share exchange agreement between Cactus Ventures, Inc. and Actinium Pharmaceuticals, Inc. The content focuses on a merger-related transaction and includes a term sheet as an exhibit. There are no financial statements or detailed financial performance data presented, only an announcement of a significant corporate transaction. This fits the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2012-12-17 English
SEPTEMBER 30, 2012 FORM 10-Q
Interim / Quarterly Report 9M 2012
2012-11-13 English
Interim / Quarterly Report 2012
Interim / Quarterly Report H1 2012
2012-08-29 English
Interim / Quarterly Report 2012
Interim / Quarterly Report H1 2012
2012-08-20 English
FORM 12B-25
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25 filed with the U.S. SEC, which is a Notification of Late Filing. It specifically states that the company, Cactus Ventures Inc, is unable to file its quarterly report on Form 10-Q for the period ended June 30, 2012 within the prescribed time period. The document does not contain the actual financial data or the quarterly report itself but is a notification explaining the delay and the expected filing date. The document length is 3243 characters, which is relatively short and consistent with a notification rather than a full report. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document notifying the SEC of a late filing, not the report itself.
2012-08-15 English
MARCH 31, 2012 10Q
Interim / Quarterly Report Q1 2012
2012-04-21 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.